Key facts
- It has raised $66.7M.
- Notable investors include Innovate UK, British Business Bank, AlbionVC, Schroders Capital, Novartis Venture Fund — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Epsilogen
- ·The full record, as it builds
Funding rounds
No funding rounds for Epsilogen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epsilogen
Operator of an immuno-oncology company intended to develop immunoglobulin antibodies for the treatment of cancer. The company's offerings include IgE-based drugs that have greater potency, enhanced tumor access, and a long tissue half-life targeting solid tumors, enabling physicians to treat their patients effectively.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2016
- Employees
- 31
- Website
- epsilogen.com/
- Ownership
- Privately Held (backing)
Epsilogen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epsilogen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epsilogen in its N-PORT filings yet. We sweep new filings monthly.